AMRX
Amneal Pharmaceuticals
$18.86
▲ +2.95%
+$0.54
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
· price updated 9h ago
Amneal Pharmaceuticals
AMRX · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · price updated 9h ago
$18.86
▲ +2.95% · +$0.54 today
AI research · $18.86
Track AMRX for continuous AI research
price position
Where AMRX sits now
52-week range
Low$7.67
High$19.26
Today $18.86
RSI (14)
69.6Neutral
03070100
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$136.3M
Total debt$2.8B
Net cash after debt$-2.7B
Valuation
What the market charges
Forward P/E
Price against expected earnings
Favorable · 14% below Sector avg · favorable
18.00x
Price / sales
Value assigned to each sales dollar
Strong · Under 3x annual sales
1.87x
Price / FCF
Price against free cash generation
Rich · Above 35x free cash flow
70.32x
EV / EBITDA
Operating value including debt
Reasonable · Between 12x and 22x EBITDA
13.13x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Strong · At least 15% return on capital
18.8%
ROE
Profit generated from shareholder equity
Strong · At least 20% return on equity
613.0%
Debt / equity
Balance-sheet leverage
Rich · Debt is above 1.5x equity
23.87x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
2.20x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How AMRX compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $5.85B | 37.9 | +9.3% | 65 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
US stock research
About Amneal Pharmaceuticals (AMRX) stock
Amneal Pharmaceuticals tracked in the US core universe. AMRX was +3.0% in the latest available session at $18.86. Its reported market value was $5.85B with a trailing P/E of 37.9. Latest reported revenue was $3.12B, changing +9.3% year over year, with $157.36M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $18.86
- Day change
- +3.0%
- Market cap
- $5.85B
- P/E (TTM)
- 37.9
- Revenue growth
- +9.3%
- Industry
- Drug Manufacturers - Specialty & Generic